Clinical Trial Update: Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Elizaria® with Soliris® in patients with Paroxysmal Nocturnal Hemoglobinuria, assessing efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Elizaria®
• SOLIRIS (eculizumab)

Snippet

Sponsor: AO GENERIUM | Conditions: Paroxysmal Nocturnal Hemoglobinuria, Marchiafava-Micheli Syndrome | Phase 3 | Status: COMPLETED